AstraZeneca Pharma India Limited has informed the Exchange about General Updates
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
AstraZeneca Pharma India informed the exchanges that SES ESG Research has assigned the company an ESG Score (Adjusted) of 64.9, which corresponds to a Grade B rating. The rating is based on publicly available information for FY 2023-24 and was independently prepared by SES — the company did not engage or pay SES for this assessment. The report was accessed by the company on June 5, 2025 and is being disclosed under SEBI's Regulation 30 read with the July 2023 circular on ESG rating disclosures. This is a routine regulatory compliance filing and does not relate to any business, operational, or financial update.
No direct impact on shareholders or stock price. This is a non-material, compliance-driven disclosure about an independently assigned ESG score and does not affect the company's financials, orders, or guidance.